News
Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the publication of detailed results from the pivotal PREEMPT CRC study in JAMA.1 The publication ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback